KLF5 and prostate carcinoma: The reduction of KLF5 expression leads to decreased mRNA level of PDGF-A together with diminished CD31-positive region ratio, hence inhibiting angiogenesis and tumor growth of prostate cancer (Nakajima et al., 2016).